Thalidomide Systematic (IUPAC) name (RS)-2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Clinical data Trade names Thalomid AHFS/Drugs.com MedlinePlus Pregnancy cat. X(AU) X(US) Legal status ℞ Prescription only Routes oral Pharmacokinetic data Protein binding 55% and 66% for the (+)-R and (–)-S enantiomers, respectively Metabolism Hepatic (CYP2C19) Half-life mean ranges from approximately 5 to 7 hours following a single dose; not altered with multiple doses Identifiers CAS number ATC code L04 PubChem DrugBank ChemSpider UNII KEGG ChEBI ChEMBL Chemical data Formula C13H10N2O4 Mol. mass 258.23 g/mol SMILES & (what is this?)
Thalidomide ( //) was introduced as a sedative drug in the late 1950s that was typically used to cure morning sickness. In 1961, it was withdrawn due to teratogenicity and neuropathy. There is now a growing clinical interest in thalidomide, and it is introduced as an immunomodulatory agent used primarily in combination with dexamethasone to treat multiple myeloma. The drug is a potent teratogen in zebrafish, chickens, rabbits and primates, including humans; severe birth defects have been reported at an exceptional level in individuals whose mother took the drug during pregnancy.
Thalidomide was sold in a number of countries across the world from 1957 until 1961, when it was withdrawn from the market after being found to be a cause of birth defects in what has been called "one of the biggest medical tragedies of modern times". It is not known exactly how many worldwide victims of the drug there have been, although estimates range from 10,000 to 20,000. Thalidomide has since been found to be a viable treatment for a number of medical conditions. It is being prescribed again in a number of countries, although its use, including its testing in the developing world, remains controversial. The thalidomide tragedy led to much stricter testing being required for drugs and pesticides before they can be licensed.
- 1 History
- 2 Possible indications
- 3 Teratogenic mechanism
- 4 Mechanism in multiple myeloma
- 5 Thalidomide analogs
- 6 Notable people affected
- 7 References
- 8 Further reading
- 9 External links
Thalidomide was developed by German pharmaceutical company Grünenthal in Stolberg (Rhineland) near Aachen. A report published by Martin W. Johnson, director of the Thalidomide Trust in the United Kingdom, mentioned evidence found by Argentinian author Carlos De Napoli that suggested the drug had been first developed as a possible antidote to nerve toxins, such as Sarin, by Otto Ambros, a Nazi scientist who joined Grünenthal after the war. Correspondence between various drug companies -- French firm Rhône-Poulenc, which was under Nazi control during the war years, Astra AB, which held the Swedish licence to distribute thalidomide, and IG Farben, the German pharmaceutical firm -- seem to confirm the existence of the product years before Grünenthal secured a patent in 1954. Furthermore, a relation between testing thalidomide and the Nazi death camps has been suggested. Grünenthal has responded to these claims by stating, "To our knowledge there was no collaboration between Grünenthal and Rhône-Poulenc for the development of Contergan/thalidomide. Three Grünenthal employees discovered thalidomide and Grünenthal is the sole inventor on the patent." According to Grünenthal, Dr. Heinrich Mückter was one of those responsible for inventing thalidomide. Other sources mark Dr. Mückter as a fledgling pharmacologist who carried out wartime experiments on Polish prisoners to find a cure for typhus, causing the death of hundreds in the process.
De Napoli suggested elsewhere that thalidomide may have been first synthesised by British scientists at the University of Nottingham in 1949. Thalidomide, launched by Grünenthal on 1 October 1957, was found to act as an effective tranquilizer and painkiller, and was proclaimed a "wonder drug" for insomnia, coughs, colds and headaches. It was also found to be an effective antiemetic that has an inhibitory effect on morning sickness, so thousands of pregnant women took the drug to relieve their symptoms. At the time of the drug's development, scientists did not believe any drug taken by a pregnant woman could pass across the placental barrier and harm the developing fetus. The Food and Drug Administration of the United States never licensed thalidomide for general use; according to Time Magazine, "In the half dozen reported U.S. cases of birth malformations due to thalidomide, the drug was obtained from abroad." However, samples had been distributed to a number of physicians as part of a clinical trial, in which 20,000 patients in the U.S. received thalidomide.
In the late 1950s and early 1960s, more than 10,000 children in 46 countries were born with deformities, such as phocomelia, as a consequence of thalidomide use. The Australian obstetrician William McBride and the German pediatrician Widukind Lenz suspected a link between birth defects and the drug, a theory Lenz proved in 1961. McBride was later awarded a number of honours, including a medal and prize money by the prestigious L'Institut de la Vie in Paris.
In the United Kingdom, the drug was licensed in 1958. Of the approximately 2,000 babies born with defects, 466 survived. The drug was withdrawn in 1961. In 1968, after a long campaign by The Sunday Times newspaper, a compensation settlement for the UK victims was reached with Distillers Company (now part of Diageo). This compensation, which is distributed by the Thalidomide Trust in the UK, was substantially increased by Diageo in 2005. The UK Government gave survivors a grant of £20 million, to be distributed through the Thalidomide Trust, in December 2009. In Germany approximately 2,500 thalidomide babies were born.
In the United States, pharmacologist and M.D. Frances Oldham Kelsey refused Food and Drug Administration (FDA) approval for an application from the Richardson-Merrell company to market thalidomide, saying further studies were needed, which reduced the impact of thalidomide in United States patients. Although thalidomide was never approved for sale in the United States, millions of tablets had been distributed to physicians during a clinical testing program. It was impossible to know how many pregnant women had been given the drug to help alleviate morning sickness or as a sedative.
Canada was the last country to stop the sales of the drug, in early 1962.
In 1962, the United States Congress enacted laws requiring tests for safety during pregnancy before a drug can receive approval for sale in the U.S. Other countries enacted similar legislation, and thalidomide was not prescribed or sold for decades.
For correctly denying the application despite the pressure from Richardson-Merrell, Kelsey eventually received the President's Award for Distinguished Federal Civilian Service at a 1962 ceremony with President John F. Kennedy. In September 2010, as noted in an article titled "The Public's Quiet Savior From Harmful Medicine", the FDA honored Dr. Kelsey with the first Kelsey award. The award, given annually to a FDA staff member, came 50 years after Dr. Kelsey, then a new medical officer at the agency, first reviewed the application from the William S. Merrell Company of Cincinnati.
Researchers soon discovered that only one particular optical isomer of thalidomide caused the teratogenicity. The pair of enantiomers, while mirror images of each other, cause different effects, although it is now known that the "safe" isomer can be converted to the teratogenic isomer once in the human body.
In 1964, Jacob Sheskin, Professor at the Hebrew University of Jerusalem at Hadassah University Hospital and the chief staff and manager of Hansen Leper Hospital in Jerusalem, administered thalidomide to a critically ill patient with erythema nodosum leprosum (ENL), a painful complication of leprosy, in an attempt to relieve his pain in spite of the ban. The patient slept for hours, and was able to get out of bed without aid upon awakening. The result was followed by more favorable experiences and then by a clinical trial. Sheskin found that patients with ENL, a painful skin condition, experienced pain relief when taking thalidomide.
Further work conducted in 1991 by Dr. Gilla Kaplan at Rockefeller University in New York City showed thalidomide worked in leprosy by inhibiting tumor necrosis factor alpha. Kaplan believed thalidomide could be an effective treatment for AIDS. He partnered with Celgene to further develop the potential for thalidomide in AIDS and tuberculosis. However, clinical trials for AIDS proved disappointing.
In 1994, Dr. Robert D'Amato at Harvard Medical School discovered thalidomide was a potent inhibitor of new blood vessel growth (angiogenesis). Numerous cancer clinical trials for thalidomide began based upon this finding. In 1997, Dr. Bart Barlogie reported thalidomide's initial effectiveness against multiple myeloma, and thalidomide was later approved in the United States by the FDA for use in this malignancy. The FDA has also approved the drug's use in the treatment of ENL. Studies are underway to determine the drug's effects on arachnoiditis and several types of cancers. However, physicians and patients alike must go through a special process, known as STEPS, to prescribe and receive thalidomide, to ensure no more children are born with birth defects traceable to the medication. Celgene has also developed analogues to thalidomide, such as lenalidomide, that are substantially more powerful and have fewer side effects — except for greater myelosuppression. Lenalidomide is now more commonly used than thalidomide for myeloma.
More recently, the World Health Organisation (WHO) has stated:
"The WHO does not recommend the use of thalidomide in leprosy as experience has shown that it is virtually impossible to develop and implement a fool-proof surveillance mechanism to combat misuse of the drug. The drug clofazimine is now a component of the multidrug therapy (MDT), introduced by WHO in 1981 as the standard treatment for leprosy and now supplied free of charge to all patients worldwide."
On July 16, 1998, the FDA approved the use of thalidomide for the treatment of lesions associated with erythema nodosum leprosum (ENL). Because of thalidomide's potential for causing birth defects, the drug may be distributed only under tightly controlled conditions. The FDA required that Celgene Corporation, which planned to market thalidomide under the brand name Thalomid, establish a system for thalidomide education and prescribing safety (STEPS) oversight program. The conditions required under the program include limiting prescription and dispensing rights only to authorized prescribers and pharmacies, keeping a registry of all patients prescribed thalidomide, providing extensive patient education about the risks associated with the drug, and providing periodic pregnancy tests for women who take the drug. On May 26, 2006, the U.S. Food and Drug Administration granted accelerated approval for thalidomide (Thalomid, Celgene Corporation) in combination with dexamethasone for the treatment of newly diagnosed multiple myeloma (MM) patients. The FDA approval came seven years after the first reports of efficacy in the medical literature and Celgene took advantage of "off-label" marketing opportunities to promote the drug in advance of its FDA approval for the myeloma indication. Thalomid, as the drug is commercially known, sold over $300 million per year, while approved only for leprosy.
Thalidomide is available to only a small number of patients in the UK, in general in specialist cancer treatment centres where research trials are taking place and where specialist doctors have experience in its use.
Brazil has the second-highest prevalence rate of leprosy in the world, and thalidomide has been used by Brazilian physicians as the drug of choice for the treatment of severe ENL since 1965. A study published in 1996 reported 33 people born in Brazil after 1965 with thalidomide embryopathy. Since 1994, the production, dispensing, and prescription of thalidomide have been strictly controlled, but cases of thalidomide embryopathy continue.
Serious infections including sepsis and tuberculosis cause the level of tumor necrosis factor-alpha (TNFα) to rise. TNFα is a chemical mediator in the body, and may enhance the wasting process in cancer patients, as well. Thalidomide may reduce the levels of TNFα, and it is possible that the drug's effect on ENL is caused by this mechanism.
Thalidomide also has potent anti-inflammatory effects that may help ENL patients. In July 1998, the FDA approved the application of Celgene to distribute thalidomide under the brand name Thalomid for treatment of ENL. Pharmion Corporation, who licensed the rights to market thalidomide in Europe, Australia, and various other territories from Celgene, received approval for its use against multiple myeloma in Australia and New Zealand in 2003. Thalomid, in conjunction with dexamethasone, is now standard therapy for multiple myeloma.
Thalidomide is also prescribed for its anti-inflammatory effects in actinic prurigo, an autoimmune skin disease. Thalidomide has been used in chronic bullous dermatosis of childhood (CBDC) with encouraging results. Peripheral neuritis may be a limiting factor for long term use of thalidomide.
Thalidomide also inhibits the growth of new blood vessels (angiogenesis), which may be useful in treating macular degeneration and other diseases. This effect helps AIDS patients with Kaposi's sarcoma, although there are better and cheaper drugs to treat the condition. Thalidomide may be able to fight painful, debilitating aphthous lesions in the mouth and esophagus of AIDS patients that prevent them from eating. The FDA formed a Thalidomide Working Group in 1994 to provide consistency between its divisions, with particular emphasis on safety monitoring. The agency also imposed severe restrictions on the distribution of Thalomid through the STEPS program.
Thalidomide is also being investigated for treating symptoms of prostate cancer, glioblastoma, lymphoma, arachnoiditis, Behçet's disease, and Crohn's disease. In a small trial, Australian researchers found thalidomide caused a doubling of the number of T cells in patients, allowing the patients' own immune system to attack cancer cells.
Studies carried out in animal models have suggested the use of combined therapy with thalidomide and glucantime could have a therapeutic benefit in the treatment of visceral leshmaniasis.
A study published in April 2010 discussed the ability of thalidomide to induce vessel maturation, which may be useful as a therapeutic strategy for the treatment of vascular malformations. The research was conducted in an experimental model of the genetic disease hereditary hemorrhagic telangiectasia.
Thalidomide and multiple myeloma
Thalidomide was first tested in humans as a single agent for the treatment of multiple myeloma in 1996 due to its antiangiogenic activity. The New England Journal of Medicine published the full study in 1999. Since then, many studies have shown that thalidomide, in combination with dexamethasone, has increased the survival of multiple myeloma patients. The combination of thalidomide and dexamethasone, often in combination with melphalan, is now one of the most common regimens for patients with newly diagnosed multiple myeloma, with an improved response rate of up to 60-70%. Thalidomide may also cause side effects, such as polyneuropathy, fatigue, skin rash, and venous thromboembolism (VTE), or blood clots, which could lead to stroke or myocardial infarction. Bennett et al. have conducted a systematic review of VTE associated with thalidomide in multiple myeloma patients. They have found that when thalidomide was administered without prophylaxis, VTE rates reached as high as 26%. Owing to the high rates of VTE associated with thalidomide in combination with dexamethasone or doxorubicin, a black box warning was added in the US in 2006 to the package insert for thalidomide, indicating that patients with multiple myeloma who receive thalidomide-dexamethasone may benefit from concurrent thromboembolism prophylaxis or aspirin. In addition, owing to these side effects, newer drugs, such as bortezomib (marketed as Velcade) and a thalidomide derivative, lenalidomide (marketed as Revlimid), have increased in popularity.
Thalidomide is racemic – it contains both left- and right-handed isomers in equal amounts. The (R) enantiomer is effective against morning sickness, but the (S) is teratogenic. The enantiomers can interconvert (racemize) in vivo – that is, if a human is given pure (R)-thalidomide or (S)-thalidomide, both isomers will later be found in the serum – therefore, administering only one enantiomer will not prevent the teratogenic effect.
The mechanism of thalidomide's teratogenic action has led to over 2000 research papers and the proposal of 15 or 16 plausible mechanisms. A theoretical synthesis in 2000 suggested the following mechanism: thalidomide intercalates (inserts itself) into DNA in guanine-cytosine-rich regions. Owing to its glutarimide part, (S) thalidomide fits neatly into the major groove of DNA at purine sites. Such intercalation impacts upon the promoter regions of the genes controlling the development of limbs, ears, and eyes, such as IGF-I and FGF-2. These normally activate the production of the cell surface attachment integrin αvβ3, with the resulting αvβ3 integrin dimer stimulating angiogenesis in developing limb buds. This then promotes the outgrowth of the bud (IGF-I and FGF-2 are also both known to stimulate angiogenesis). Therefore, by inhibiting the chain of events, thalidomide causes the truncation of limb development. In 2009, this theory received strong support, with research showing "conclusively that loss of newly formed blood vessels is the primary cause of thalidomide teratogenesis, and developing limbs are particularly susceptible because of their relatively immature, highly angiogenic vessel network."
Inactivation of the protein cereblon
Thalidomide binds to and inactivates the protein cereblon, which is important in limb formation. The inactivation leads to a teratogenic effect on fetal development. This was confirmed when the scientists, using genetic techniques, reduced the production of cereblon in developing chick and zebrafish embryos. These embryos had defects similar to those treated with thalidomide. While the mechanism that causes teratogenicity has been established, the mechanism for other therapeutic effects remains unclear.
Mechanism in multiple myeloma
Thalidomide appears to inhibit the disease progression in multiple myeloma by several mechanisms, as resulting mainly from experiments on myeloma cancer cell lines:
- Inhibition of the production of interleukin-6 (IL-6), which is a growth factor for the proliferation of myeloma cells
- Activation of apoptotic pathways through caspase 8-mediated cell death
- At the mitochondrial level, thalidomide results in induction of c-jun terminal kinase (JNK)-dependent release of cytochrome-c and Smac into the cytosol of cells, affecting apoptosis.
- Activation of T cells to produce IL-2, thereby altering the amount and function of natural killer cells (NK cells), thus augmenting the activity of NK-dependent cytotoxicity
The exploration of the antiangiogenic and immunomodulatory activities of thalidomide has led to the study and creation of thalidomide analogs. In 2005, Celgene received FDA approval for lenalidomide (Revlimid) as the first commercially useful derivative. Revlimid is available only in a restricted distribution setting to avoid its use during pregnancy. Further studies are being conducted to find safer compounds with useful qualities. Another analog, pomalidomide, is in the clinical trial phase. These thalidomide analogs can be used to treat different diseases, or used in a regimen to fight two conditions.
Notable people affected
- Rock Brynner, son of Yul Brynner, author of Dark Remedy, who took Thalidomide as an adult for his immune disorder
- Mat Fraser, musician, actor and performance artist born with phocomelia of both arms
- Alvin Law, radio broadcaster, born without arms
- Louise Medus Mansell, daughter of David Mason, campaigner for increased compensation for thalidomide children, born with no arms or legs
- Tony Meléndez, award winning singer and guitarist who plays with his feet, is known internationally due to the recognition received from Pope John Paul II and U.S. President Ronald Reagan.
- Thomas Quasthoff, an internationally acclaimed bass-baritone, who describes himself: "1.34 meters tall, short arms, seven fingers — four right, three left — large, relatively well-formed head, brown eyes, distinctive lips; profession: singer"
- Niko von Glasow produced a documentary called Nobody's Perfect, based on the lives of 12 people affected by the drug, which was released in 2008.
- Terry Wiles, born with phocomelia of both arms and legs, has become known internationally through the television drama On Giant's Shoulders and the best-selling book of the same name.
- A 2007 fiction book Thalidomide Kid by author Kate Rigby described a story about a boy born with no arms confronting pain and prejudice during the 1970s.
- ^ Ando Y, Fuse E, Figg WD (June 1, 2002). "Thalidomide metabolism by the CYP2C subfamily". Clin Cancer Res 8 (6): 1964–73. PMID 12060642. http://clincancerres.aacrjournals.org/cgi/pmidlookup?view=long&pmid=12060642. Retrieved 2009-06-18.
- ^ a b "Thalidomide survivors to get £20m". BBC News. 23 December 2009. http://news.bbc.co.uk/1/hi/8428838.stm. Retrieved 26 July 2011.
- ^ Ito T, Ando H, Suzuki T, et al. (March 2010). "Identification of a primary target of thalidomide teratogenicity". Science 327 (5971): 1345–50. doi:10.1126/science.1177319. PMID 20223979. http://www.sciencemag.org/cgi/pmidlookup?view=short&pmid=20223979.
- ^ Thalidomide: Drug safety during pregnancy and breastfeeding / DRUGSAFETYSITE.COM
- ^ Anon. "Thalidomide — A Second Chance? — programme summary". BBC. http://www.bbc.co.uk/science/horizon/2004/thalidomide.shtml. Retrieved 2009-05-01.
- ^ a b Anon. "Born Freak". Happy Birthday Thalidomide. Channel 4. http://www.channel4.com/life/microsites/B/bornfreak/birthday.html. Retrieved 2009-05-01.
- ^ Washington, Harriet A. (January 14, 2011). "Prudence and the Pill: Testing Thalidomide in the Global South". http://www.biopoliticaltimes.org/article.php?id=5504.
- ^ Anon (March 10, 2006). "Thalidomide:controversial treatment for multiple myeloma". Health news. http://www.healthyforms.com/health-news/2006/03/thalidomide-controversial-treatment.php. Retrieved 2009-05-01\. [dead link]
- ^ Bowditch, Gillian (March 26, 2006). "Can thalidomide ever be trusted?". The Sunday Times (London: News International Limited). http://www.timesonline.co.uk/tol/news/uk/scotland/article695193.ece?token=null&offset=0&page=1. Retrieved 2009-05-01.
- ^ a b Heaton, C. A. (1994). The Chemical Industry. Springer. pp. 40. ISBN 0751400181.
- ^ Foggo, Daniel (2009-02-08). "Thalidomide 'was created by the Nazis'". London: The Times. http://www.timesonline.co.uk/tol/life_and_style/health/article5683577.ece. Retrieved 2009-06-18.
- ^ Foggo, Daniel (13 September 2009). "Thalidomide victim Gary Syner to go on hunger strike". The Sunday Times (London: Times Newspapers Ltd.). http://www.timesonline.co.uk/tol/life_and_style/health/article6832320.ece. Retrieved 2009-09-28.
- ^ Moghe, Vijay V; Ujjwala Kulkarni, Urvashi I Parmar (2008). "Thalidomide" (PDF). Bombay Hospital Journal (Bombay: Bombay Hospital) 50 (3): 446. http://www.bhj.org/journal/2008_5003_july/download/page-472-476.pdf. Retrieved 25 October 2009.
- ^ "Medicine: The Thalidomide Disaster". Time. 10 August 1962. http://www.time.com/time/magazine/article/0,9171,873697-1,00.html. Retrieved 15 April 2011.
- ^ Mekdeci, Betty. "How a Commonly Used Drug Caused Birth Defects". http://www.birthdefects.org/research/bendectin_1.php.
- ^ Bren, Linda (2001-02-28). "Frances Oldham Kelsey: FDA Medical Reviewer Leaves Her Mark on History". FDA Consumer (US Food and Drug Administration). http://permanent.access.gpo.gov/lps1609/www.fda.gov/fdac/features/2001/201_kelsey.html. Retrieved 2009-12-23.
- ^ Anon. "Widukind Lenz". who name it?. Ole Daniel Enersen. http://www.whonamedit.com/doctor.cfm/1002.html. Retrieved 2009-05-01.
- ^ a b c Anon (2002-06-07). "Thalidomide:40 years on". BBC news (BBC). http://news.bbc.co.uk/1/hi/uk/2031459.stm. Retrieved 2009-05-01.
- ^ Report of Thalidomide at University of New South Wales. See also main William McBride article.
- ^ "Apology for thalidomide survivors". BBC News:Health (BBC News). 14 January 2010. http://news.bbc.co.uk/1/hi/health/8458855.stm. Retrieved 2010-01-14.
- ^ Ryan, Caroline (1 April 2004). "They just didn't know what it would do". BBC News:Health (BBC news). http://news.bbc.co.uk/1/hi/health/3589173.stm. Retrieved 2009-05-01.
- ^ Flintoff, John-Paul (March 23, 2008). "Thalidomide: the battle for compensation goes on". The Sunday Times (London: Times Newspapers Ltd.). http://www.timesonline.co.uk/tol/life_and_style/health/article3602694.ece. Retrieved 2009-05-01.
- ^ "Compensation offer on Thalidomide". BBC News. 7 July 2005. http://news.bbc.co.uk/1/hi/health/4658919.stm. Retrieved 26 July 2011.
- ^ Mekdeci, Betty. "How a Commonly Used Drug Caused Birth Defects". http://www.birthdefects.org/research/bendectin_1.php.
- ^ "Turning Points of History — Prescription for Disaster". History Television. http://www.history.ca/ontv/titledetails.aspx?titleid=21267. Retrieved 24 February 2010.
- ^ a b c Burkholz, Herbert (1997-09-01). "Giving Thalidomide a Second Chance". FDA Consumer (US Food and Drug Administration). http://www.fda.gov/fdac/features/1997/697_thal.html. Retrieved 2006-09-21.
- ^ Thalidomide - medic8.com - Retrieved August 25, 2008
- ^ "The Public’s Quiet Savior From Harmful Medicines". The New York Times. September 13, 2010. http://www.nytimes.com/2010/09/14/health/14kelsey.html?_r=1&8dpc.
- ^ Eccles H; Ratcliff B (2001). Chemistry 2. Cambridge University Press. pp. 170. ISBN 978-0-521-79882-2.
- ^ Ligham, Alex (April 2000). "Optical Isomerism In Thalidomide". Thalidomide. http://www.chm.bris.ac.uk/motm/thalidomide/optical2iso.html. Retrieved 2009-05-02.
- ^ Silverman, MD, William (2002-04-22). "The Schizophrenic Career of a "Monster Drug"". Pediatrics 110 (2): 404–6. doi:10.1542/peds.110.2.404. PMID 12165600. http://pediatrics.aappublications.org/cgi/content/full/110/2/404.
- ^ Rao KV (September 2007). "Lenalidomide in the treatment of multiple myeloma". American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists 64 (17): 1799–807. doi:10.2146/ajhp070029. PMID 17724360.
- ^ Anon. "Use of thalidomide in leprosy". WHO:leprosy elimination. WHO. http://www.who.int/lep/research/thalidomide/en/index.html. Retrieved 22 April 2010.
- ^ FDA, Center for Drug Evaluation and Research, July 16, 1998
- ^ FDA Approves Thalomid (thalidomide) to Treat Multiple Myeloma
- ^ Desikan, R; N. Munsi, J. Zeldis et al. (1999). "Activity of thalidomide (THAL) in multiple myeloma (MM) confirmed in 180 patients with advanced disease". Blood 94 (Suppl. 1): 603a–603a.
- ^ Ismail, MA (2005-07-07). "FDA: A Shell of its Former Self". Pushing Prescriptions. The Centre for Public Integrity. http://projects.publicintegrity.org/rx//report.aspx?aid=722.
- ^ Anon. "Thalidomide". Cancer treatments. Cancerbackup. http://www.cancerbackup.org.uk/Treatments/Biologicaltherapies/Angiogenesisinhibitors/Thalidomide. Retrieved 2009-05-01.
- ^ Castilla, E.E.; et al. (1996). "Thalidomide, a current teratogen in South America". Teratology (Wiley-Liss) 54 (6): 273–7. doi:10.1002/(SICI)1096-9926(199612)54:6<273::AID-TERA1>3.0.CO;2-#. PMID 9098920. http://www.fundaciongillow.org/publicaciones/articulo4.pdf.
- ^ Paumgartten, FJ; Chahoud, I; Chahoud, Ibrahim (July 2006). "Thalidomide embryopathy cases in Brazil after 1965". Reproductive Toxicology 22 (1): 1, 2. doi:10.1016/j.reprotox.2005.11.007. PMID 16427249. http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6TC0-4J2W0DX-1&_user=899537&_rdoc=1&_fmt=&_orig=search&_sort=d&view=c&_acct=C000047642&_version=1&_urlVersion=0&_userid=899537&md5=064ddf875924b5b116f6ed8d82049b07.
- ^ Correio Braziliense (January 2006). Talidomida volta a assustar. http://www.saude.df.gov.br/003/00301009.asp?ttCD_CHAVE=31041.
- ^ Rouhi, Maureen. "Thalidomide". Chemical & Engineering News. American Chemical Society. http://pubs.acs.org/cen/coverstory/83/8325/8325thalidomide.html. Retrieved 2006-09-21.
- ^ Madnani NA, Khan KJ (2010). "Linear IgA bullous dermatosis of childhood: Response to thalidomide". Indian Journal of Dermatology, Venereology, and Leprology 76 (4): 427. doi:10.4103/0378-6323.66601. PMID 20657136. http://www.ijdvl.com/article.asp?issn=0378-6323;year=2010;volume=76;issue=4;spage=427;epage=429;aulast=Madnani.
- ^ Brown, RD; Spencer A, Ho PJ, Kennedy N, Kabani K, Yang S, Sze DM, Aklilu E, Gibson J, Joshua DE (2009 Nov). "Prognostically significant cytotoxic T cell clones are stimulated after thalidomide therapy in patients with multiple myeloma". Leukemia & Lymphoma 50 (11): 1860–4. doi:10.3109/10428190903216804. PMID 19883313.
- ^ Ghassem, Solgi; Kariminia A., Abdi K, Darabi M, Ghareghozloo B. (March 2006). "Effects of combined therapy with thalidomide and glucantime on leishmaniasis induced by Leishmania major in BALB/c mice" (PDF). Korean Journal of Parasitology 44 (1): 55–61. doi:10.3347/kjp.2006.44.1.55. PMC 2532651. PMID 16514283. http://synapse.koreamed.org/Synapse/Data/PDFData/0066KJP/kjp-44-55.pdf.
- ^ Lebrin, Franck; Srun S., Raymond2] K, Martin S., van den Brink S, Freitas C., Bréant C., Mathivet T., Larrivée B., Thomas J., Arthur H., Westermann C., Disch F., Mager J., Snijder R., Eichmann A., Mummery C. (April 2010). "Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia". Nature Medicine 16 (4): 420–8. doi:10.1038/nm.2131. PMID 20364125. http://www.nature.com/nm/journal/v16/n4/full/nm.2131.html.
- ^ Singhal S, Mehta J, Desikan R, et al. (November 1999). "Antitumor activity of thalidomide in refractory multiple myeloma". The New England Journal of Medicine 341 (21): 1565–71. doi:10.1056/NEJM199911183412102. PMID 10564685. http://content.nejm.org/cgi/pmidlookup?view=short&pmid=10564685&promo=ONFLNS19. Retrieved 2009-06-18.
- ^ Gieseler F (June 2008). "Pathophysiological considerations to thrombophilia in the treatment of multiple myeloma with thalidomide and derivates". Thrombosis and Haemostasis 99 (6): 1001–7. doi:10.1160/TH08-01-0009. PMID 18521500.
- ^ Denz U, Haas PS, Wäsch R, Einsele H, Engelhardt M (July 2006). "State of the art therapy in multiple myeloma and future perspectives". European Journal of Cancer (Oxford, England : 1990) 42 (11): 1591–600. doi:10.1016/j.ejca.2005.11.040. PMID 16815703.
- ^ Haas PS, Denz U, Ihorst G, Engelhardt M (April 2008). "Thalidomide in consecutive multiple myeloma patients: single-center analysis on practical aspects, efficacy, side effects and prognostic factors with lower thalidomide doses". Eur. J. Haematol. 80 (4): 303–9. doi:10.1111/j.1600-0609.2007.01022.x. PMID 18182082.
- ^ Bennett CL, Angelotta C, Yarnold PR, et al. (December 2006). "Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer". JAMA 296 (21): 2558–60. doi:10.1001/jama.296.21.2558-c. PMID 17148721.
- ^ Teo SK, Colburn WA, Tracewell WG, Kook KA, Stirling DI, Jaworsky MS, Scheffler MA, Thomas SD, Laskin OL (2004). "Clinical pharmacokinetics of thalidomide". Clin Pharmacokinet. 43 (5): 311–327. doi:10.2165/00003088-200443050-00004. PMID 15080764.
- ^ a b c d Stephens TD, Bunde CJ, Fillmore BJ (June 2000). "Mechanism of action in thalidomide teratogenesis". Biochemical Pharmacology 59 (12): 1489–99. doi:10.1016/S0006-2952(99)00388-3. PMID 10799645.
- ^ Koch HP, Czejka MJ (1986). "Evidence for the intercalation of thalidomide into DNA: clue to the molecular mechanism of thalidomide teratogenicity?". Z. Naturforsch., C, J. Biosci. 41 (11–12): 1057–61. PMID 2953123.
- ^ Huang PH, McBride WG (1997). "Interaction of [glutarimide-2-14C]-thalidomide with rat embryonic DNA in vivo". Teratogenesis, Carcinogenesis, and Mutagenesis 17 (1): 1–5. doi:10.1002/(SICI)1520-6866(1997)17:1<1::AID-TCM2>3.0.CO;2-L. PMID 9249925.
- ^ Therapontos C, Erskine L, Gardner ER, Figg WD, Vargesson N (May 2009). "Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation". Proceedings of the National Academy of Sciences of the United States of America 106 (21): 8573–8. doi:10.1073/pnas.0901505106. PMC 2688998. PMID 19433787. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2688998. Retrieved 2009-06-18.
- ^ Carl Zimmer (March 15, 2010). "Answers Begin to Emerge on How Thalidomide Caused Defects". New York Times. http://www.nytimes.com/2010/03/16/science/16limb.html?ref=science&pagewanted=all. Retrieved 2010-03-21. "As they report in the current issue of Science, a protein known as cereblon latched on tightly to the thalidomide."
- ^ Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y, Yamaguchi Y, Handa H (2010). "Identification of a primary target of thalidomide teratogenicity". Science 327 (5971): 1345–1350. doi:10.1126/science.1177319. PMID 20223979. http://www.sciencemag.org/cgi/content/abstract/327/5971/1345. Lay summary – BBC News.
- ^ a b c d Anderson, K. C. (2005). "Lenalidomide and Thalidomide: Mechanisms of Action—Similarities and Differences". Seminars in Hematology 42 (4 Suppl 4): S3–S8. doi:10.1053/j.seminhematol.2005.10.001. PMID 16344099.
- ^ Search of: pomalidomide — ClinicalTrials.gov
- ^ Raghupathy R, Billett HH (March 2009). "Promising therapies in sickle cell disease". Cardiovasc Hematol Disord Drug Targets 9 (1): 1–8. doi:10.2174/187152909787581354. PMID 19275572. http://www.benthamdirect.org/pages/content.php?CHDDT/2009/00000009/00000001/0001X.SGM.
- ^ Dreifus, Claudia (2001-07-31). "A Conversation with Rock Brynner — A 'Dark Remedy' Is Now Generating Light". The New York Times. http://www.nytimes.com/2001/07/31/health/a-conversation-with-rock-brynner-a-dark-remedy-is-now-generating-light.html?pagewanted=1. Retrieved 2010-10-11.
- ^ Courtenay-Smith, Natasha (2008-04-23). "A truly special love story: Two married thalidomide survivors living happily 50 years after drug's launch". London: The Daily Mail. http://www.dailymail.co.uk/news/article-561360/A-truly-special-love-story-Two-married-thalidomide-survivors-living-happily-50-years-drugs-launch.html. Retrieved 2009-06-18.
- ^ Orpheus lives: A small good thing in Quastoff Retrieved on 2008-10-22
- ^ Nobody's Perfect Release Dates
- ^ Movie Review of Nobody's Perfect
- ^ "(Interview) Kate Rigby, author of ‘Thalidomide Kid’". Leicester Review of Books. November 19, 2007. http://leicesterreviewofbooks.wordpress.com/2007/11/19/interview-kate-rigby-author-of-thalidomide-kid/. Retrieved 2011-09-29. "My latest book is about a boy called Daryl affected by the Thalidomide tragedy (he has no arms) and the way he copes with his disability through humor (he calls himself ‘Thalidomide Kid’). At the heart of the story is the burgeoning romance between Daryl and the deputy head’s daughter, Celia, and the pains and prejudice they face in a 70s school setting."
- Stephens, Trent; Brynner, Rock (2001-12-24). Dark Remedy: The Impact of Thalidomide and Its Revival as a Vital Medicine. Perseus. ISBN 0-7382-0590-7.
- Knightley, Phillip; Evans, Harold. Potter, Elaine. Wallace, Marjorie. (1979). Suffer The Children: The Story of Thalidomide. New York: The Viking Press. ISBN 0-670-68114-8.
- Thalidomide monograph from Chemical and Engineering News. (Archived by WebCite® at http://www.webcitation.org/5nWHyOCfI)
- Thalidomide product monograph (Needs registration)
- Multiple Myeloma Research Foundation article on Thalidomide
- International Myeloma Foundation article on Thalidomide
- Thalidomide — Annotated List of Links (covering English and German pages)
- WHO Pharmaceuticals Newsletter No. 2, 2003 - See page 11, Feature Article
- Grünenthal GmbH — Thalidomide
- Celgene website on Thalomid
- The Return of Thalidomide — BBC
- CBC Digital Archives – Thalidomide: Bitter Pills, Broken Promises
- Thalidomide UK
- The Thalidomide Trust
- The International Contergan Thalidomide Alliance website
- "The Big Pitch: How would you conduct a campaign for the new Thalidomide Drugs?", forum of pharmaceutical and medical marketing professionals commenting on how they would address the thalidomine controversies.
Immunomodulators: Immunosuppressive drugs / Immunosuppressants (L04) Intracellular
(initiation)TNF-α inhibitorThalidomide • Lenalidomide
CD3 (Muromonab-CD3, Otelixizumab, Teplizumab, Visilizumab) • CD4 (Clenoliximab, Keliximab, Zanolimumab) • CD11a (Efalizumab) • CD18 (Erlizumab) • CD20 (Afutuzumab, Rituximab, Ocrelizumab, Pascolizumab) • CD23 (Gomiliximab, Lumiliximab) • CD40 (Teneliximab, Toralizumab) • CD62L/L-selectin (Aselizumab) • CD80 (Galiximab) • CD147/Basigin (Gavilimomab) • CD154 (Ruplizumab)T-lymphocyte (Zolimomab aritox)Unsorted-cept (Fusion)
Wikimedia Foundation. 2010.